JP2023527454A - 中鎖トリグリセリドを使用して点頭てんかんを処置する方法 - Google Patents

中鎖トリグリセリドを使用して点頭てんかんを処置する方法 Download PDF

Info

Publication number
JP2023527454A
JP2023527454A JP2022573444A JP2022573444A JP2023527454A JP 2023527454 A JP2023527454 A JP 2023527454A JP 2022573444 A JP2022573444 A JP 2022573444A JP 2022573444 A JP2022573444 A JP 2022573444A JP 2023527454 A JP2023527454 A JP 2023527454A
Authority
JP
Japan
Prior art keywords
spasms
composition
day
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527454A5 (https=
Inventor
ウォーカー，ジュディス
ヘンダーソン，サミュエル・ティー
Original Assignee
セレシン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレシン・インコーポレーテッド filed Critical セレシン・インコーポレーテッド
Publication of JP2023527454A publication Critical patent/JP2023527454A/ja
Publication of JP2023527454A5 publication Critical patent/JP2023527454A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022573444A 2020-05-29 2021-05-28 中鎖トリグリセリドを使用して点頭てんかんを処置する方法 Pending JP2023527454A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032111P 2020-05-29 2020-05-29
US63/032,111 2020-05-29
US202163176747P 2021-04-19 2021-04-19
US63/176,747 2021-04-19
PCT/US2021/034883 WO2021243226A1 (en) 2020-05-29 2021-05-28 Methods for the treatment of infantile spasms using medium chain triglycerides

Publications (2)

Publication Number Publication Date
JP2023527454A true JP2023527454A (ja) 2023-06-28
JP2023527454A5 JP2023527454A5 (https=) 2024-05-28

Family

ID=78744111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573444A Pending JP2023527454A (ja) 2020-05-29 2021-05-28 中鎖トリグリセリドを使用して点頭てんかんを処置する方法

Country Status (8)

Country Link
US (1) US20230181512A1 (https=)
EP (1) EP4157250A4 (https=)
JP (1) JP2023527454A (https=)
KR (1) KR20230018462A (https=)
CN (1) CN115884766A (https=)
AU (1) AU2021281426A1 (https=)
CA (1) CA3184353A1 (https=)
WO (1) WO2021243226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595638A4 (en) * 2017-03-15 2020-09-16 Cerecin Inc. PHARMACEUTICAL COMPOSITIONS WITH HIGH DRUG LOADS BASED ON MEDIUM-CHAIN TRIGLYCERIDES AND RELATED METHODS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
US20190091178A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164089A0 (en) * 2002-04-30 2005-12-18 Suntory Ltd Astaxanthin medium-chain fatty acidester, production method of the same, and composition comprising the same
KR20070034591A (ko) * 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
CA2882708A1 (en) * 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
EP3462885A4 (en) * 2016-05-27 2020-01-22 Insys Development Company, Inc. STABLE CANNABINOID FORMULATIONS
AU2017347778A1 (en) * 2016-10-24 2019-05-16 University Of South Florida Delaying latency to seizure by combinations of ketone supplements
CN110678173B (zh) * 2017-04-10 2023-03-28 维塔弗洛国际有限公司 用于治疗癫痫的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US20190091178A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAIN & DEVELOPMENT, vol. 40, JPN6025019800, 2018, pages 724 - 727, ISSN: 0005595457 *
CURRENT DEVELOPMENTS IN NUTRITION, vol. 1, no. 4, JPN6025019799, 2017, pages 000257, ISSN: 0005595458 *

Also Published As

Publication number Publication date
CN115884766A (zh) 2023-03-31
US20230181512A1 (en) 2023-06-15
CA3184353A1 (en) 2021-12-02
AU2021281426A1 (en) 2023-02-02
WO2021243226A1 (en) 2021-12-02
EP4157250A1 (en) 2023-04-05
EP4157250A4 (en) 2024-06-19
KR20230018462A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
KR101634083B1 (ko) 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
US20070135376A1 (en) Method to reduce oxidative damage and improve mitochondrial efficiency
US20100261791A1 (en) Compositions and Methods for Improving or Preserving Brain Function
CN104010634B (zh) 用于治疗神经系统病症的组合物
EP3873442A1 (en) Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
JP2016535036A (ja) 消化不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素
EP1605950A2 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
US20230346699A1 (en) Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications
JP2023527454A (ja) 中鎖トリグリセリドを使用して点頭てんかんを処置する方法
JP2016535037A (ja) 非機械的基礎を有する吸収不良の処置における使用のためのモノアシルグリセロール及び脂溶性栄養素
US20240415793A1 (en) Neuroprotective composition comprising pyruvate and citrate
US12171735B2 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
EP3622951A1 (en) Agent for raising total ketone concentration, oil and fat composition, pharmaceutical composition, and food product composition
WO2023022984A1 (en) Methods for the treatment of migraine and related headache symptoms using tricaprylin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260226

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260325